| [1] |
Oh DY,Venook AP,Fong L. On the Verge: Immunotherapy for colorectal carcinoma[J]. J Natl Compr Canc Netw, 2015, 13(8): 970-978.
|
| [2] |
Shankaran V,Ikeda H,Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity[J]. Nature, 2001, 410(6832): 1107-1111.
|
| [3] |
Pernot S,Terme M,Voron T, et al. Colorectal cancer and immunity: what we know and perspectives[J]. World J Gastroenterol, 2014, 20(14): 3738-3750.
|
| [4] |
Bystrom J,Taher TE,Muhyaddin MS, et al. Harnessing the Therapeutic Potential of Th17 Cells[J]. Mediators Inflamm, 2015, 2015: 205156.
|
| [5] |
Ge J,Zhu L,Zhou J, et al. Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese[J]. J Cancer Res Clin Oncol, 2015, 141(9): 1533-1544.
|
| [6] |
Mojtahedi Z,Mohmedi M,Rahimifar S, et al. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer[J]. Gene, 2012, 508(2): 229-232.
|
| [7] |
Topalian SL,Hodi FS,Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454.
|
| [8] |
Brahmer JR,Drake CG,Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 2010, 28(19): 3167-3175.
|
| [9] |
Chung KY,Gore I,Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer[J]. J Clin Oncol, 2010, 28(21): 3485-3490.
|
| [10] |
Hu C,Anderson AC,Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity[J]. Nat Immunol, 2005, 6(12): 1245-1252.
|
| [11] |
Chen J,Chen Z. The effect of immune microenvironment on the progression and prognosis of colorectal cancer[J]. Med Oncol, 2014, 31(8): 82.
|
| [12] |
CDX-1127 Program Update, November 2013 at SITC 2013,
URL
|
| [13] |
Linch SN,McNamara MJ,Redmond WL. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal[J]. Front Oncol, 2015, 5: 34.
|
| [14] |
Pedroza-Gonzalez A,Verhoef C,Ijzermans JN, et al. Activated tumor-infiltrating CD4＋regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer[J]. Hepatology, 2013, 57(1): 183-194.
|
| [15] |
Cepowicz D,Gryko M,Zareba K, et al. Assessment of activity of an adhesion molecule CD134 and CD137 in colorectal cancer patients[J]. Pol Przegl Chir, 2011, 83(12): 641-645.
|
| [16] |
Vonderheide RH,Burg JM,Mick R, et al. Phase I study of the CD40 agonist antibody CP-870, 893 combined with carboplatin and paclitaxel in patients with advanced solid tumors[J]. Oncoimmunology, 2013, 2(1): e23033.
|
| [17] |
Xiao Y,Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy[J]. Cancer Discov, 2015, 5(1): 16-18.
|
| [18] |
Cooper ZA,Reuben A,Amaria RN, et al. Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma[J]. Oncoimmunology, 2014, 3(9): e954956.
|
| [19] |
Singh PP,Sharma PK,Krishnan G, et al. Immune checkpoints and immunotherapy for colorectal cancer[J]. Gastroenterol Rep (Oxf), 2015, 3(4): 289-297.
|
| [20] |
Kroemer G,Galluzzi L,Zitvogel L, et al. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?[J]. Oncoimmunology, 2015, 4(7): e1058597.
|